
Anticoagulation with edoxaban is not beneficial in patients with atrial high-rate episodes without clinically defined AF, as it does not reduce the risk of cardiovascular death, stroke, or systemic embolism but increases bleeding risk.


coremsg

Among patients with atrial high-rate episodes detected by implantable devices, anticoagulation with edoxaban did not show a benefit but did increase bleeding risk in the NOAH-AFNET 6 trial.

Anticoagulation Edoxaban Trial Results